Background The angiotensin-converting enzyme (ACE) plays an important role in the production of angiotensin II and the degradation of bradykinin, two peptides involved in cardiovascular homeostasy. Presence of a polymorphism in the ACE gene (ACE Ss) has been postulated from segregation analysis of plasma ACE in families. This putative polymorphism, which strongly affects the plasma and cellular levels of ACE, probably by modulating ACE gene transcription, has not yet been identified at the molecular level; however, an insertion/deletion polymorphism is present in the 16th intron of the ACE gene (ACE I/D) and appears to be a very good marker for ACE Ss. The biological role of ACE suggests that the ACE gene polymorphism could affect the predisposition to myocardial infarction (MI).
and activity45 of plasma and cellular ACE, ie, levels are higher in homozygotes for the D allele than in homozygotes for the I allele and are intermediate in heterozygotes. The ACE I/D polymorphism is a marker for the postulated functional variant ACE Ss and is associated with 28% to 44% of the interindividual variability of plasma ACE activity or immunoreactivity level.34 Recently, in a large multicenter case-control study (ECTIM) , an increased risk of myocardial infarction (MI) and an increased frequency of parental MI were demonstrated in subjects carrying the ACE D allele, 8, 9 in particular in patients conventionally considered low risk. 8 These observations suggested that a high plasma ACE level might be associated with an increased risk of coronary heart disease (CHD). To further assess this hypothesis, the activity of plasma ACE now has been measured in a large subsample of the ECTIM study, and the relation between plasma ACE level and MI has been analyzed.
Methods Study Populations and Sampling of Patients and Control Subjects
The ECTIM study was pendent studies in populations covered by World Health Organization/MONICA CHD registers: Belfast and its surroundings in Northern Ireland; Strasbourg and the department of Bas-Rhin in the northeast of France; Toulouse and the department of Haute-Garonne in the southwest of France; and Lille and its suburbs in the north of France.10 Men 25 to 64 years old were eligible for inclusion in the study; they had to reside in the region, and their parents and grandparents had to have been born in Europe (for the French centers) or in the historical entity of Ulster (Northern Ireland).
During the study period, all male patients surviving a definite MI (not necessarily a first MI), defined by MONICA criteria (category I), were eligible for the study. The patients were drawn from the MONICA registers, and further epidemiological data and blood samples were obtained at least 3 months, and at most 9 months, after the event.
Samples of population were obtained from the electoral rolls in France, and from the lists of general practitioners held by the Central Services Agency in Northern Ireland. Stratification by age was employed to match approximately the age distribution of the population samples with that of the patients. Among the eligible control subjects, 40% in Belfast, 54% in Strasbourg, 49% in Toulouse, and 47% in Lille refused to take part, did not respond, or could not be traced.
After informed consent was obtained, the control subjects were examined in clinics or, if necessary, at home by specially trained staff. A set of questionnaires was Genotyping of the ACE Gene Insertion/Deletion Polymorphism Genomic DNA was prepared from white blood cells by phenol extraction, and genotyping of the ACE I/D polymorphism was done as previously described.7
Statistical Analysis
Plasma ACE levels were compared between groups by ANOVA, using the GLM procedure of the SAS statistical software. Logistic regression (LOGIST procedure) comparing patients and control subjects was used to assess the independent effects of the ACE I/D polymorphism and plasma ACE level on MI risk after adjustment on covariates. The heterogeneity of association according to age was tested by introducing interaction terms in the ANOVAs. Adjustment on population was performed in all analyses. Since no significant heterogeneity across populations was detected, only global results are shown in the tables. Analysis of the distribution of plasma ACE in patients and control subjects was performed by commingling analysis,1' conditioned on marker genotype (see "Appendix").
Results
Plasma ACE activity and the ACE I/D polymorphism were assessed simultaneously in 1086 subjects (471 and 615 in the MI and population samples, respectively). The mean plasma ACE levels of the MI and population samples were 30.8 (SEM 0.5) U/L and 29.5 (0.4) U/L, respectively (P<.05) and were homogeneous across populations. The mean age of the two samples was similar: 54.0 (0.4) and 53.5 (0.3), respectively (nonsignificant difference). As expected, there was a strong association between plasma ACE and the ACE I/D polymorphism, the mean level of plasma ACE increasing with the number of D alleles (P<.0001 in patients and in control subjects). Globally, no significant difference in plasma ACE levels between patients and control subjects was detected ( whereas in patients, it significantly decreased with age (r=-.225, P<.0001). The test of homogeneity of the correlation coefficients was highly significant (P<.001).
To take into account this interaction, the study population was divided according to the median of age (Table  2 ). In the group <55 years old, mean plasma ACE level was higher in patients than in control subjects within each ACE I/D genotype (P<.01), and the reverse was observed in those .55 years (P<.07). In individuals .60 years old, the difference was even more marked (P<.01). The effects of plasma ACE level and of the ACE I/D polymorphism on the risk of MI were assessed by logistic regression analysis adjusted on population (Table 3). The two variables were tested separately because of the strong correlation between them. In the group <55 years old, plasma ACE level was a significant predictor of MI (P<.008; P<.007 after adjustment on other risk factors) but not ACE I/D. The opposite situation was observed in the group .55 years old: the ACE I/D polymorphism was related to the risk (P<.07; P<.03 after adjustment on other risk factors) but not plasma ACE. As a consequence of these two contrasting patterns, the ACE I/D polymorphism was only weakly associated with MI in the whole study population (P<.07; P<.07 after adjustment on other risk factors). *Commingling analysis of the three conditional distributions of plasma ACE: ,u(ss), g(sS), p(SS) are the estimated means of the postulated genotypes ss, sS, and SS, respectively, Ir(S) is the probability of allele S, MI(lIS) is the probability of allele given S, i(lis) is the probability of allele given s, and cr is the residual standard deviation.
Strategy used in the commingling analysis: The most general model (model 1) assumed that the genotype-specific means, the frequency of allele S, and the association between the Ss and l/D loci were different in patients and control subjects. Successive models then were tested with increasing numbers of parameters assumed identical in patients and control subjects. Comparison of successive models was made by the likelihood ratio test.
No departure from Hardy-Weinberg proportions at the postulated Ss locus was detected in either patients or control subjects. The association between alleles at the postulated Ss and observed l/D loci was similar in patients and control subjects (model 4 vs model 2). Marker allele was preferentially associated with allele s, but its frequency conditional to allele S [iT(lIS)] was significantly different from 0 (P<.01), indicating that the linkage disequilibrium between the susceptibility and marker loci was not complete.
genotype in patients and control subjects. The results of the commingling analyses of these within genotypes distributions are given in Table 5 . A trimodal distribution was much better supported by the data than a unimodal or a bimodal distribution (P<.0001). The three modes and the residual intragenotype SDs were not significantly different between patients and control subjects (Table 5 , model 2 versus model 1), suggesting that they might reflect the plasma ACE distributions associated with the three genotypes SS, Ss, and ss inferred from the family studies. 2, 4 In the whole population, the frequency of the postulated allele S was not significantly different in cases and controls (model 5 versus model 4), and the postulated Ss polymorphism explained 65% and 60% of the variance of plasma ACE in these two groups, respectively, a value also close to that inferred from the family studies. Figs 3 and 4 show the distribution of plasma ACE levels in patients and control subjects <55 years and .55 years, respectively. In the younger age group, the commingling analysis (Table 6 , first column) gave good support for a mixture of three subdistributions with similar means and common SDs in patients and control subjects. The postulated allele S was more frequent in patients than in control subjects: 0.47 (SD 0.05) versus 0.36 (0.04), but the frequency of allele I conditional on S (probability for S to carry I) was also larger in patients than in control subjects 0.16 (0.04) versus 0.06 (0.03).
The global difference for these two parameters between patients and control subjects was highly significant (P<.007). In the older subjects, the commingling analysis (Table 6 , second column) did not reveal any difference in the distribution of plasma ACE between patients and control subjects. In control subjects, the frequency of the postulated allele S did not differ according to age, but in patients there was an apparent depletion of S in the older age group compared with the younger one (0.32 versus 0.47, P<.005). these percentages may be the consequence of random fluctuation or of different methods used to assess plasma ACE.
Plasma ACE activity in the absence of circulating inhibitors is proportional to the number of molecules of enzyme, as measured by radioimmunoassay.'2 Increased plasma ACE levels have been observed repeatedly during chronic ACE inhibitor treatment13'14 and are probably a result of an induction of ACE synthesis in endothelial cells,1516 most likely mediated at the transcriptional level. The regulatory factor responsible for the induction remains unknown. Induction was observed in this study probably because blood was taken at distance from the last drug intake and also because of the lack of stability of sulfhydryl-containing inhibitors in plasma samples. Also, the high dilution of the sample in the assay might have favored the dissociation of the ACE-inhibitor complex if residual inhibitor was present in the plasma. A larger induction was observed in this study in subjects heterozygote or homozygote for the D allele. The influence of the polymorphism on induction was codominant in patients, whereas in the population samples the effect was weaker in DD homozygotes than in heterozygotes. This is probably a chance finding resulting from the small number of treated subjects, homozygotes for allele D, in the population samples. The genotype-dependent induction of ACE by ACE inhibitors suggests that the ACE functional polymorphism not only alters the basal level of transcription but also modulates the ACE gene response to regulatory factors. This may be similar to the genotype-dependent increase in plasma ACE levels previously reported in children.2 Induction of ACE gene expression also has been observed in hypertrophied hearts and in vascular smooth muscle cells after endothelial injury in the rat. '7 If this phenomenon occurs in humans, it would be of interest to determine whether it is also modulated by the ACE gene polymorphism. In our study, the prescription of ACE inhibitors was not controlled; the genotype-dependent induction of ACE synthesis by ACE inhibitors therefore should be considered a hypothesis, which will have to be tested in controlled studies where plasma ACE level is assessed before and during treatment.
We previously reported that the ACE DD genotype was positively associated with MI in the ECTIM study with a population-adjusted odds ratio of 1.34 when compared with ID+II individuals. The smaller odds ratio estimated in the present analysis (1.28) is due to the noninclusion of individuals for whom measurement of plasma ACE was not available or who were treated with ACE inhibitors. Overall, 24% of patients and 22% of control subjects were excluded for these reasons, most of them from France. This tended to increase the proportion of participants from Belfast in the sample and to lower the odds ratio for MI associated with the DD genotype, since no association was found between the polymorphism and MI in the whole sample in Belfast. In the low-risk group, however, the odds ratio for MI of DD versus ID+11 individuals was quite similar to that found in the previous analysis of the ECTIM data (3.0, P<.0025).
From our previous family studies,2,4 we suspected that the ACE I/D polymorphism was only a marker for a putative functional variant (denoted Ss) controlling plasma ACE level. It was thus of interest to determine whether plasma ACE level provided additional information to the I/D polymorphism regarding the contribution of the ACE gene to the risk of MI in the ECTIM study. Plasma ACE level was very homogeneous across the four populations, was unrelated with age in control subjects, but decreased with age in patients. As a consequence, in the older subjects, patients tended to have a lower mean level of plasma ACE than control subjects whereas in younger subjects, patients had consistently higher mean levels of plasma ACE than control subjects within the three ACE I/D genotypes. This interaction could reflect the fact that plasma ACE is a risk factor only in the younger age group but also is compatible with the underrepresentation of patients with high plasma ACE levels in older MI subjects (see detailed discussion below).
Given the important differences in plasma ACE levels between patients and control subjects younger than 55 years and the lack of difference in older individuals, a series of commingling analyses of plasma ACE were performed to see whether this observation could receive a genetic interpretation. The results of the analyses in the whole sample demonstrated the presence of three subdistributions of plasma ACE, which probably correspond to the three putative ACE genotypes ss, sS, and SS. The modes of these subdistributions were found at the same plasma ACE levels in patients and control subjects and were compatible with the genotypic means inferred from the segregation analysis of plasma ACE in families.24 The percentage of variance of plasma ACE explained by the putative Ss polymorphism was approximately 60% in both patients and control subjects; this value is very close to that inferred from family studies and should be compared with the 20% of variance of plasma ACE level explained by the ACE I/D marker polymorphism. The main conclusions of the commingling analyses were:
(1) Before age 55, the postulated allele S was more frequent in patients than in control subjects: 0.47 and 0.36, respectively, but the genotype-specific means were not different between patients and control subjects. This result suggests that the case-control difference of plasma ACE level observed in this age group was explained largely by the different frequencies of the postulated allele S in patients and control subjects. The predicted frequencies of the postulated genotypes SS, Ss, and ss, assuming random pairing of alleles, were, respectively, 0.22, 0.50, and 0.28 in patients and 0.13, 0.46, and 0.41 in control subjects. If codominance is assumed, the derived odds-ratios for MI of SS and Ss with respect to ss were 2.5 and 1.6, respectively.
(2) The frequency of the postulated allele S in patients dropped from 0.47 before age 55 to 0.32 after (P<.005). As already suggested, high levels of plasma ACE could be a risk factor for MI only in the younger individuals. However, it is important to consider that this age-related difference in allele frequency could also be the consequence of selection by death, if those developing an MI and carrying S were more prone to die from their disease. This possibility is in accordance with a couple of observations made in the ECTIM study. First, we have shown that the ACE DD genotype was more strongly related to MI in subjects at low risk of explanation for this finding is selection by death of high-risk DD individuals. Second, parental history of fatal MI was associated with the ACE D allele in the offspring,9 and this association was stronger than what would have been predicted from the difference between patients and control subjects. Again this discrepancy could be the consequence of a high lethality in DD patients with MI, which could affect the case-control comparison. In the ECTIM study, patients were included 3 to 9 months after occurrence of MI. Several sources of evidence suggest that approximately 30% of the patients who develop an acute coronary event die before hospitalization and that during the first 3 months after hospitalization, about 8% of the hospitalized patients die from a complication of their MI. Such selection could strongly affect the frequency of a risk factor for death in MI survivors. The results of a recently completed study of the ACE I/D polymorphism in patients who died of an MI in Belfast have confirmed that deceased patients have a higher frequency of the ACE D allele than control subjects. 18 Although the difference between patients and control subjects of plasma ACE in the younger age group was compatible with the presence of an underlying major gene effect, we cannot exclude the possibility that plasma ACE activity might also be altered in the post-MI phase, even 3 to 9 months after disease onset. This is a usual shortcoming of phenotype measurement in retrospective studies. However, several arguments suggest that the higher mean ACE level in cases is not secondary to MI: (a) The modes of the subdistributions of plasma ACE in the three ACE I/D genotypes were similar in patients and control subjects. In subjects c55 years old (Fig 3) L(x,m)=l:g P(x,mig)P(g)= 1g P(xlg)P(mjg)P(g) where x is the trait, m is the marker genotype, and g is the susceptibility genotype underlying the trait. P(g) is the prior probability of the genotypes. If we denote s and S the two alleles at the susceptibility locus and I and D the two alleles at the marker locus, P(g) and P(mig) are parameterized in terms of ir(S), the frequency of S, and ir(IIS) and n(Iis), the frequencies of I conditional to allele S and s, respectively. These conditional probabilities are functions of the linkage disequilibrium between the two loci. Under linkage equilibrium w(IIS)=17(lls), P(xlg) is the penetrance function conditional on the genotype underlying the trait. It is assumed to be distributed normally with genotype-specific means ,(SS), ,u(Ss), and ,u(ss), and common SD cr. In the more general model, parameters were allowed to differ between patients and control subjects. Specific hypotheses were tested by means of the likelihood ratio test.
